ENDRA Life Sciences Inc (NDRA) Actualités

Form 8-K - Current report

ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it has regained...

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update

Company accelerated enrollment in global multisite pilot study and significantly reduced operating expenses while refocusing resources to...

Study Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting® 2024

ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced the acceptance of a poster...

ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent

Global Intellectual Property Portfolio Now Includes 82 Issued Patents ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic...

Form 8-K - Current report

Form 8-K - Current report

ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany

Scans first patient in post-CE mark clinical study with Munich’s center of excellence in Europe’s largest healthcare market ENDRA Life Sciences...

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report